Can a cheaper copy match the original diabetes pill?
NCT ID NCT07763912
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This trial compares two oral medications containing sitagliptin and metformin in extended-release tablets. The goal is to see if the test version is absorbed in the body the same way as the reference product, a process called bioequivalence. Healthy adults aged 18 to 55 will receive a single dose of each medication under fed conditions, with blood samples taken to measure drug levels. The study uses a crossover design, meaning each participant gets both treatments at different times, to ensure a fair comparison.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sitagliptin/metformin extended-release tablet
- What this could lead to
- If the generic tablet proves bioequivalent, it could offer a more affordable alternative to the brand-name diabetes medication, expanding patient access.
- What could go wrong
- This is a small, early-stage study in healthy volunteers, not patients. Results may not predict real-world effectiveness or safety in people with diabetes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOEQUIVALENCE are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Axis Clinicals Latina, S.A. de C.V.
Mexico City, Mexico City, 07870, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.